Abstract
The eosinophil-derived neurotoxin (EDN, also known as eosinophil protein-X) is best-known as one of the four major proteins found in the large specific granules of human eosinophilic leukocytes. Although it was named for its discovery and initial characterization as a neurotoxin, it is also expressed constitutively in human liver tissue and its expression can be induced in macrophages by proinflammatory stimuli. EDN and its divergent orthologs in rodents have ribonuclease activity, and are members of the extensive RNase A superfamily, although the relationship between the characterized physiologic functions and enzymatic activity remains poorly understood. Recent explorations into potential physiologic functions for EDN have provided us with some insights into its role in antiviral host defense, as a chemoattractant for human dendritic cells, and most recently, as an endogenous ligand for toll-like receptor (TLR)2.
Keywords: Inflammation, Ribonuclease, Toll-like receptor, Dendritic cell, Leukocyte
Current Pharmaceutical Biotechnology
Title: Eosinophil-Derived Neurotoxin / RNase 2: Connecting the Past, the Present and the Future
Volume: 9 Issue: 3
Author(s): H. F. Rosenberg
Affiliation:
Keywords: Inflammation, Ribonuclease, Toll-like receptor, Dendritic cell, Leukocyte
Abstract: The eosinophil-derived neurotoxin (EDN, also known as eosinophil protein-X) is best-known as one of the four major proteins found in the large specific granules of human eosinophilic leukocytes. Although it was named for its discovery and initial characterization as a neurotoxin, it is also expressed constitutively in human liver tissue and its expression can be induced in macrophages by proinflammatory stimuli. EDN and its divergent orthologs in rodents have ribonuclease activity, and are members of the extensive RNase A superfamily, although the relationship between the characterized physiologic functions and enzymatic activity remains poorly understood. Recent explorations into potential physiologic functions for EDN have provided us with some insights into its role in antiviral host defense, as a chemoattractant for human dendritic cells, and most recently, as an endogenous ligand for toll-like receptor (TLR)2.
Export Options
About this article
Cite this article as:
Rosenberg F. H., Eosinophil-Derived Neurotoxin / RNase 2: Connecting the Past, the Present and the Future, Current Pharmaceutical Biotechnology 2008; 9 (3) . https://dx.doi.org/10.2174/138920108784567236
DOI https://dx.doi.org/10.2174/138920108784567236 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Connectivity Studies in Schizophrenia: Unravelling the Effects of Antipsychotics
Current Neuropharmacology P2X7 Receptor Orchestrates Multiple Signalling Pathways Triggering Inflammation, Autophagy and Metabolic/Trophic Responses
Current Medicinal Chemistry Reactive Species, Cellular Repair and Risk Factors in the Onset of Type 2 Diabetes Mellitus: Review and Hypothesis
Current Diabetes Reviews Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Genetic Studies in Relation to Kuru: An Overview
Current Molecular Medicine DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Current Neuropharmacology Oxytosis: A Novel Form of Programmed Cell Death
Current Topics in Medicinal Chemistry Cellular Entry of HIV: Evaluation of Therapeutic Targets
Current Pharmaceutical Design Association of Cerebrospinal Fluid Adiponectin Levels With Cerebral Glucose Metabolism In Mild Cognitive Impairment: A Pilot Study
Current Alzheimer Research BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design Zolpidem Therapy for Movement Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research The Glutamatergic Neurotransmission in the Central Nervous System
Current Medicinal Chemistry Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry Breast Cancer Risks in Premenopausal Women: A Review
Current Women`s Health Reviews Development and Applications of Non-HIV-Based Lentiviral Vectors in Neurological Disorders
Current Gene Therapy